Pluronic F127-chitosan modified magnesium oxide hybrid nanomaterials prepared via a one-pot method: Potential uses in antibacterial and anticancer agents

Abstract

The utilization of Organic/inorganic hybrid nanomaterials (HNMs) combining chitosan (Cs)-Pluronic F127 (PF) and magnesium oxide (MgCsPF) has considerably augmented the antibacterial, anticancer, and biocompatibility properties, thus playing a pivotal role in the biomedical industry. This study aims to synthesize a MgCsPF HNMs capable of effectively eradicating negative bacterial infections and cervical cancer Hela cells while ensuring no harmful effects on normal fibroblast cells. Various techniques are employed to analyze the biological, physical, and chemical characteristics of the synthesized HNMs. The antibacterial and anticancer properties of the MgCsPF HNMs rely on the generation of active free radicals (ROS), which is influenced by various factors, including particle size, larger surface area, oxygen vacancy, ion release, and diffusion ability. These factors contribute to the enhanced production of ROS, leading to effective antibacterial and anticancer effects of the MgCsPF HNMs. The antibacterial activity of MgCsPF HNMs showed enhanced antibacterial activity compared to MgO when tested against a variety of Gram-negative bacteria. The zone of inhibition is between 11 to 16 mm. Furthermore, the anticancer activity of the synthesized Cs, PF127, MgO, and MgCsPF HNMs is evaluated against cervical cancer HeLa cells. The IC50 values for cell inhibition were 14.2 μg/mL for MgCsPF HNMs, 22.8 μg/mL for Cs, 24.8 μg/mL for PF, and 17.5 μg/mL for MgO. The results demonstrate that MgCsPF HNMs exhibit superior anticancer properties compared to Cs, PF, and MgO samples. Consequently, MgCsPF HNMs show promise for application in the biomedical industry, given their desirable antibacterial and anticancer properties, as well as biocompatibility.